Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
HIV/AIDS Blog Central

Victrelis in the Spotlight for HIV/HCV-Coinfected Patients

By Barbara McGovern, M.D.

March 26, 2012

News from the latest major HIV research conference continues to look great for hepatitis C (HCV) cures.

More results from a Victrelis (boceprevir) treatment trial were unveiled at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) in Seattle, Wash. The researchers showed results of treatment 12 weeks after 95 HIV-infected patients with HCV genotype 1 infection had finished 48 weeks of treatment with either a) PEG interferon plus ribavirin plus placebo (i.e., dual therapy, which has been the standard of treatment for many years) or b) PEG interferon plus ribavirin plus Victrelis (i.e., triple therapy).

The 12-week, "off-treatment" data show how much better triple therapy is than dual therapy. The percentage of patients who still had no detectable HCV in their blood was 61 percent in the triple-therapy group compared to 27 percent in the dual-therapy group.

The side effects were the same ones seen in the Victrelis trials that involved patients with HCV alone: mainly anemia (loss of red blood cells) and a bad taste in the mouth.

Advertisement
These encouraging results suggest that triple therapy is going to improve the treatment outcomes in coinfected patients by a wide margin. The final, 24-week post-treatment data will be presented later in the year. Bigger trials of triple therapy in HIV/HCV-coinfected patients are planned.

However, there is also the problem of drug interactions, which makes us remember that the treatment of HCV in the HIV-infected patient is certainly not straightforward, and we need to proceed with caution.

At CROI 2012, the maker of Victrelis showed data on drug interactions with HIV medications in 39 healthy volunteers. These persons were given one HIV protease inhibitor (e.g., Kaletra [lopinavir/ritonavir], Prezista [darunavir, TMC114] or Reyataz [atazanavir]) for about three weeks. Then they took the same HIV protease inhibitor in combination with Victrelis. Unfortunately, the combinations led to low blood levels of these HIV protease inhibitors. This can affect HIV control.

In addition, Kaletra and Prezista both cut down the levels of Victrelis. This can affect HCV treatment responses.

Meanwhile, in another study, the combination of Victrelis and the integrase inhibitor Isentress (raltegravir) did not lead to any drug interactions of concern.

So at this time, if you are taking Victrelis triple therapy and you are on an HIV protease inhibitor, contact your doctor to discuss these new study results -- but do so before you stop any of your medications, since stopping medications entirely may more quickly lead to resistance.

When you talk to your doctor, you may want to ask whether you need to switch around your HIV medications. Right now, Truvada (tenofovir/FTC) plus Isentress seems to be the safest bet among the standard first-line treatment options.

If you have questions about treating HIV/hepatitis C coinfection, Dr. McGovern is available to answer them! Visit our "Ask the Experts" forum on Hepatitis & HIV Coinfection to ask Dr. McGovern your question or browse her archive of answers.

Get email notifications every time this blog is updated.

See Also
Talk to a Physician About HIV/Hepatitis Coinfection in Our "Ask the Experts" Forums
More News on Hepatitis C Treatment
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:
BLOG:
Making Progress on HCV Treatment in HIV-Infected Patients


Barbara McGovern, M.D., is an associate professor of medicine at the Tufts University School of Medicine and an attending physician in the Division of Infectious Diseases at Lemuel Shattuck Hospital in Boston. She is a widely published researcher and frequent lecturer on issues pertaining to HIV and coinfections with hepatitis B and hepatitis C. More information about Dr. McGovern is available on her bio page.


Subscribe to Barbara's Blog:

Subscribe by RSSBy RSS ?

Subscribe by Email


Recent Posts:


View All Posts


A Brief Disclaimer:

The opinions expressed by TheBody.com's bloggers are entirely their own, and do not necessarily reflect the views of TheBody.com itself.

Advertisement